Therapeutic plasma exchange in thrombotic thrombocytopenic purpura

Joly, 2017, Thrombotic thrombocytopenic purpura, Blood, 129, 2836, 10.1182/blood-2016-10-709857 Moschcowitz, 1925, An acute febrile pleiochromic anemia with hyaline thrombosis of the terminal arterioles and capillaries: an undescribed disease, Arch Intern Med, 36, 89, 10.1001/archinte.1925.00120130092009 Rubinstein, 1959, Unusual remission in a case of thrombotic thrombocytopenic purpura syndrome following fresh blood exchange transfusions, Ann Intern Med, 51, 1409, 10.7326/0003-4819-51-6-1409 Bukowski, 1976, Exchange transfusions in the treatment of thrombotic thrombocytopenic purpura, Semin Hematol, 13, 219 Byrnes, 1977, Treatment of thrombotic thrombocytopenic purpura with plasma, N Engl J Med, 297, 1386, 10.1056/NEJM197712222972507 Taft, 1979, Thrombotic thrombocytopenic purpura and dose of plasma exchange, Blood, 54, 842, 10.1182/blood.V54.4.842.842 Rock, 1991, Comparison of plasma exchange with plasma infusion in the treatment of thrombotic thrombocytopenic purpura, N Engl J Med, 325, 393, 10.1056/NEJM199108083250604 Lian, 1979, Presence of a platelet aggregating factor in the plasma of patients with thrombotic thrombocytopenic purpura (TTP) and its inhibition by normal plasma, Blood, 53, 333, 10.1182/blood.V53.2.333.333 Moake, 1982, Unusually large plasma factor VIII: von Willebrand factor multimers in chronic relapsing thrombotic thrombocytopenic purpura, N Engl J Med, 307, 1432, 10.1056/NEJM198212023072306 Tsai, 1996, Physiologic cleavage of von Willebrand factor by a plasma protease is dependent on its conformation and requires calcium ion, Blood, 87, 4235, 10.1182/blood.V87.10.4235.bloodjournal87104235 Furlan, 1996, Partial purification and characterization of a protease from human plasma cleaving von Willebrand factor to fragments produced by in vivo proteolysis, Blood, 87, 4223, 10.1182/blood.V87.10.4223.bloodjournal87104223 Tsai, 1998, Antibodies to von Willebrand factor–cleaving protease in acute thrombotic thrombocytopenic purpura, N Engl J Med, 339, 1585, 10.1056/NEJM199811263392203 Rieger, 2005, ADAMTS13 autoantibodies in patients with thrombotic microangiopathies and other immunomediated diseases, Blood, 106, 1262, 10.1182/blood-2004-11-4490 Levy, 2001, Mutations in a member of the ADAMTS gene family cause thrombotic thrombocytopenic purpura, Nature, 413, 488, 10.1038/35097008 Schwartz, 2016, Guidelines on the use of therapeutic apheresis in clinical practice-evidence-based approach from the Writing Committee of the American Society for Apheresis: the seventh special issue: therapeutic apheresis-guidelines 2016, J Clin Apheresis, 31, 149 Scully, 2017, Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies, J Thromb Haemost, 15, 312, 10.1111/jth.13571 Pereira, 1995, Thrombotic thrombocytopenic purpura/hemolytic uremic syndrome: a multivariate analysis of factors predicting the response to plasma exchange, Ann Hematol, 70, 319, 10.1007/BF01696619 Novitzky, 1994, The treatment of thrombotic thrombocytopenic purpura: plasma infusion or exchange?, Br J Haematol, 87, 317, 10.1111/j.1365-2141.1994.tb04915.x Coppo, 2003, High-dose plasma infusion versus plasma exchange as early treatment of thrombotic thrombocytopenic purpura/hemolytic-uremic syndrome, Medicine (Baltimore), 82, 27, 10.1097/00005792-200301000-00003 Zafrani, 2018, Does this patient with thrombotic thrombocytopenic purpura have a cardiac involvement?, Intensive Care Med, 44, 893, 10.1007/s00134-018-5243-4 Lemaire, 2017, Plasma exchange in the intensive care unit: technical aspects and complications, J Clin Apheresis, 32, 405, 10.1002/jca.21529 Knöbl, 2003, Immunoadsorption for the treatment of a patient with severe thrombotic thrombocytopenic purpura resistant to plasma exchange: kinetics of an inhibitor of ADAMTS13: letters to the editors, J Thromb Haemost, 1, 187, 10.1046/j.1538-7836.2003.00004.x O’Brien, 2013, The use of 50% albumin/plasma replacement fluid in therapeutic plasma exchange for thrombotic thrombocytopenic purpura: fifty percent albumin/plasma fluid for TPE in TTP, J Clin Apheresis, 28, 416, 10.1002/jca.21288 Riviere, 2015, Platelet transfusion and catheter insertion for plasma exchange in patients with thrombotic thrombocytopenic purpura and a low platelet count: PLT transfusion for catheter insertion in TTP, Transfusion (Paris), 55, 1798, 10.1111/trf.13041 Coppo, 2001, Effectiveness of platelet transfusions after plasma exchange in adult thrombotic thrombocytopenic purpura: a report of two cases, Am J Hematol, 68, 198, 10.1002/ajh.1179 Som, 2012, Decreasing frequency of plasma exchange complications in patients treated for thrombotic thrombocytopenic purpura-hemolytic uremic syndrome, 1996 to 2011 (CME): plasma exchange complications in TTP, Transfusion (Paris), 52, 2525, 10.1111/j.1537-2995.2012.03646.x Hacquard, 2012, Evaluation of the hemostatic potential including thrombin generation of three different therapeutic pathogen-reduced plasmas: hemostatic potential of therapeutic plasma, Vox Sang, 102, 354, 10.1111/j.1423-0410.2011.01562.x Toussaint-Hacquard, 2015, Type of plasma preparation used for plasma exchange and clinical outcome of adult patients with acquired idiopathic thrombotic thrombocytopenic purpura: a French retrospective multicenter cohort study: therapeutic plasma and TTP outcome, Transfusion (Paris), 55, 2445, 10.1111/trf.13229 Guignier, 2018, Amotosalen-inactivated plasma is as equally well tolerated as quarantine plasma in patients undergoing large volume therapeutic plasma exchange, Transfus Clin Biol, 25, 73, 10.1016/j.tracli.2017.10.002 Mintz, 2006, A randomized, controlled Phase III trial of therapeutic plasma exchange with fresh-frozen plasma (FFP) prepared with amotosalen and ultraviolet A light compared to untreated FFP in thrombotic thrombocytopenic purpura, Transfusion (Paris), 46, 1693, 10.1111/j.1537-2995.2006.00959.x Herbrecht, 2018, Characterization of efficacy and safety of pathogen inactivated and quarantine plasma in routine use for treatment of acquired immune thrombotic thrombocytopenic purpura, Vox Sang, 113, 459, 10.1111/vox.12663 de la Rubia, 2001, Role of methylene blue-treated or fresh-frozen plasma in the response to plasma exchange in patients with thrombotic thrombocytopenic purpura, Br J Haematol, 114, 721, 10.1046/j.1365-2141.2001.02991.x Alvarez-Larran, 2004, Methylene blue-photoinactivated plasma vs. fresh-frozen plasma as replacement fluid for plasma exchange in thrombotic thrombocytopenic purpura, Vox Sang, 86, 246, 10.1111/j.0042-9007.2004.00506.x del Río-Garma, 2008, Methylene blue-photoinactivated plasma versus quarantine fresh frozen plasma in thrombotic thrombocytopenic purpura: a multicentric, prospective cohort study, Br J Haematol, 143, 39, 10.1111/j.1365-2141.2008.07292.x Rock, 2005, Does cryosupernatant plasma improve outcome in thrombotic thrombocytopenic purpura? No answer yet, Br J Haematol, 129, 79, 10.1111/j.1365-2141.2005.05418.x Röthele, 2000, Design of the prospective randomized study for the treatment of patients with thrombotic microangiopathy. PRODROMI Study Group, Ther Apher, 4, 327, 10.1046/j.1526-0968.2000.004005327.x Zeigler, 2001, Cryoprecipitate poor plasma does not improve early response in primary adult thrombotic thrombocytopenic purpura (TTP), J Clin Apheresis, 16, 19, 10.1002/jca.1003 Cataland, 2017, Cyclosporine or steroids as an adjunct to plasma exchange in the treatment of immune-mediated thrombotic thrombocytopenic purpura, Blood Adv, 1, 2075, 10.1182/bloodadvances.2017009308 The Italian TTP Study Group, 2010, High versus standard dose methylprednisolone in the acute phase of idiopathic thrombotic thrombocytopenic purpura: a randomized study, Ann Hematol, 89, 591, 10.1007/s00277-009-0877-5 Jasti, 2008, Rituximab as an adjunct to plasma exchange in TTP: a report of 12 cases and review of literature, J Clin Apheresis, 23, 151, 10.1002/jca.20172 Ling, 2009, Sustained response with rituximab in patients with thrombotic thrombocytopenic purpura: a report of 13 cases and review of the literature, Am J Hematol, 84, 418, 10.1002/ajh.21439 de la Rubia, 2010, Efficacy and safety of rituximab in adult patients with idiopathic relapsing or refractory thrombotic thrombocytopenic purpura: results of a Spanish multicenter study, Transfus Apher Sci, 43, 299, 10.1016/j.transci.2010.09.018 Page, 2016, Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura, Blood, 127, 3092, 10.1182/blood-2016-03-703827 Scully, 2007, Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS-13, Br J Haematol, 136, 451, 10.1111/j.1365-2141.2006.06448.x Froissart, 2012, Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center, Crit Care Med, 40, 104, 10.1097/CCM.0b013e31822e9d66 Mcdonald, 2010, Rituximab pharmacokinetics during the management of acute idiopathic thrombotic thrombocytopenic purpura: PK of rituximab in TTP, J Thromb Haemost, 8, 1201, 10.1111/j.1538-7836.2010.03818.x Scully, 2011, A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. Blood, 118, 1746 Hie, 2014, Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura, Blood, 124, 204, 10.1182/blood-2014-01-550244 Jestin, 2018, Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura, Blood, 132, 2143, 10.1182/blood-2018-04-840090 Soucemarianadin, 2016, Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience, Eur J Haematol, 97, 183, 10.1111/ejh.12706 Nguyen, 2007, Twice-daily plasma exchange for patients with refractory thrombotic thrombocytopenic purpura: the experience of the Oklahoma Registry, 1989 through 2006, Transfusion (Paris), 48, 349 Sayani, 2015, How I treat refractory thrombotic thrombocytopenic purpura, Blood, 125, 3860, 10.1182/blood-2014-11-551580 Patriquin, 2016, Bortezomib in the treatment of refractory thrombotic thrombocytopenic purpura, Br J Haematol, 173, 779, 10.1111/bjh.13993 Knöbl, 2009, Anti-von Willebrand factor aptamer ARC1779 for refractory thrombotic thrombocytopenic purpura, Transfusion (Paris), 49, 2181, 10.1111/j.1537-2995.2009.02232.x Cataland, 2012, Initial experience from a double-blind, placebo-controlled, clinical outcome study of ARC1779 in patients with thrombotic thrombocytopenic purpura, Am J Hematol, 87, 430, 10.1002/ajh.23106 Feys, 2012, Inhibition of von Willebrand factor-platelet glycoprotein Ib interaction prevents and reverses symptoms of acute acquired thrombotic thrombocytopenic purpura in baboons, Blood, 120, 3611, 10.1182/blood-2012-04-421248 Peyvandi, 2016, Caplacizumab for acquired thrombotic thrombocytopenic purpura, N Engl J Med, 374, 511, 10.1056/NEJMoa1505533 Peyvandi, 2017, Caplacizumab reduces the frequency of major thromboembolic events, exacerbations and death in patients with acquired thrombotic thrombocytopenic purpura, J Thromb Haemost, 15, 1448, 10.1111/jth.13716 Scully, 2019, Caplacizumab treatment for acquired thrombotic thrombocytopenic purpura, N Engl J Med, 380, 335, 10.1056/NEJMoa1806311 Schiviz, 2012, A new mouse model mimicking thrombotic thrombocytopenic purpura: correction of symptoms by recombinant human ADAMTS13, Blood, 119, 6128, 10.1182/blood-2011-09-380535 Plaimauer, 2011, Recombinant ADAMTS13 normalizes von Willebrand factor-cleaving activity in plasma of acquired TTP patients by overriding inhibitory antibodies: rADAMTS13 overrides inhibitors in TTP plasma. J Thromb Haemost, 9, 936 Jian, 2012, Gain-of-function ADAMTS13 variants that are resistant to autoantibodies against ADAMTS13 in patients with acquired thrombotic thrombocytopenic purpura, Blood, 119, 3836, 10.1182/blood-2011-12-399501 Chen, 2011, N-acetylcysteine reduces the size and activity of von Willebrand factor in human plasma and mice, J Clin Invest, 121, 593, 10.1172/JCI41062 Li, 2014, Treatment of refractory thrombotic thrombocytopenic purpura with N-acetylcysteine: a case report: treatment of TTP with N-Acetylcysteine, Transfusion (Paris), 54, 1221, 10.1111/trf.12440 Tersteeg, 2017, N-acetylcysteine in preclinical mouse and baboon models of thrombotic thrombocytopenic purpura, Blood, 129, 1030, 10.1182/blood-2016-09-738856 Coppo, 2019, Thrombotic thrombocytopenic purpura: toward targeted therapy and precision medicine, Res Pract Thromb Haemost, 3, 26, 10.1002/rth2.12160 Coppo, 2010, Predictive features of severe acquired ADAMTS13 deficiency in idiopathic thrombotic microangiopathies: the French TMA Reference Center Experience. Morty RE, editor, PLoS ONE, 5, e10208, 10.1371/journal.pone.0010208 Bendapudi, 2017, Derivation and external validation of the PLASMIC score for rapid assessment of adults with thrombotic microangiopathies: a cohort study, Lancet Haematol, 4, e157, 10.1016/S2352-3026(17)30026-1